Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen

Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen

<b>Objective: </b> Tamoxifen is used as a complementary treatment for estrogen receptor (ER)-positive breast cancer (BCa), but many patients developed resistance. The aim of this study was to examine the role of syndecan-binding protein (SDCBP) silencing in ER-positive BCa cells.<b>...

Full description

Bibliographic Details
Main Authors: Jun Zhang, Xiaolong Qian, Fangfang Liu, Xiaojing Guo, Feng Gu, Li Fu
Format: Article
Language:English
Published: China Anti-Cancer Association 2018-03-01
Series:Cancer Biology & Medicine
Subjects:
Syndecan-binding protein (SDCBP)
tamoxifen
breast cancer
endocrine-therapy resistance
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1088

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1088

Similar Items